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 2	
Introduction 3	
The application of molecular genetics strategies into the clinical practice highlighted the existence of 4	
a large gap between the genotype and phenotype in many human disorders [1-2]. This is particularly 5	
true for neuromuscular disorders which consist of a heterogenous group of pathologies characterized 6	
by progressive weakness and wasting of proximal and/or distal muscles [3-4]. The phenotypic 7	
overlap, the limited availability of muscle biopsies and the multi-systemic events occurring in 8	
neuromuscular disorders raised the need for a multidisciplinary approach to provide an accurate 9	
diagnosis and allow targeted interventions according to the profile of each patient [3-4]. Our group is 10	
one of the two Italian Reference Centers for the genetic characterization of Facioscapulohumeral 11	
muscular Dystrophy (FSHD, OMIM #158900). FSHD affects approximately 1 in 8300 individuals 12	
[5-7]. The disease is characterized by clinical variability and incomplete penetrance, ranging from 13	
asymptomatic to wheelchair-dependent individuals [2]. Patients experience a progressive weakness 14	
of scapular girdle, facial and humeral muscles in the initial stage of FSHD. Later, the weakness can 15	
extend to the muscles of trunk and of lower-extremities, leading thereby to loss of ambulation in 20% 16	
of cases [8-9]. Two forms of FSHD are known, namely FSHD1 and FSHD2, which are characterized 17	
by identical clinical features but different genetic signatures. 18	
FSHD1 accounts for approximately 95% of cases and it is associated with a contraction of a 19	
microsatellite repeat array on 4q35 chromosome [2]. This region is 3.3 kb long and is referred to as 20	
D4Z4 region. In healthy individuals, the repeat consists of 11 to 100 Repeated Units (RU), whereas 21	
it is found to be 1-10 RU in FSHD1 patients. The array contraction results in the hypomethylation of 22	
D4Z4 and, consequently, in the expression of Double Homeobox Protein 4 (DUX4) that is toxic for 23	
muscle cells [10-11]. However, it is important to remark that as many as 2% of the general population 24	
presents 8-10 RU without being affected [2]. These findings suggested that the etiopathogenesis of 25	
FSHD might not be due to the D4Z4 contraction on 4q35 alone, but to a combination of specific 26	
genetic and epigenetic signatures, which create a permissive background for the development of 27	
disease.  28	
Approximately 5% of patients show clinical symptoms typical of FSHD, without carrying a short 29	
allele on D4Z4 repeat array. This form is clinically identical to FSHD1 but genetically distinct and it 30	
is termed FSHD2 (OMIM #158901) [12]. FSHD2 has been associated with mutations in Structural 31	
Maintenance of Chromosomes flexible Hinge Domain containing 1 (SMCHD1, 18p11.32, OMIM 32	
#614982) gene. SMCHD1 consists of 48 exons and encodes the homonymous protein belonging to 33	
the highly conserved SMC protein family, although it is also regarded as a member of the human 34	
Microrchidia (MORC) family. Both these groups of proteins are involved in the epigenetic regulation 35	
of the chromatin status [13-14]. In fact, SMCHD1 is mainly involved in the regulation of high-order 36	
chromosome structures, in the inactivation of X chromosome and generally in the epigenetic 37	
regulation of chromatin repression [14-15]. In particular, SMCHD1 contributes to the somatic 38	
repression of DUX4 by directly binding to D4Z4 repeat array [16]. SMCHD1 protein harbors a N-39	
terminal GHKL-ATPase domain and a non-canonical C-terminal SMC hinge domain, both flanked by 40	
coiled-coil regions and uncharacterized domains. These functional domains are involved in the 41	
homodimerization of the protein, which is regarded as a fundamental mechanism for its activity [15]. 42	
The mutational spectrum of SMCHD1 includes small deletions, splice site mutations and missense 43	
mutations [17]. These mutations decrease the binding activity of SMCHD1, resulting in D4Z4 44	
hypomethylation and incomplete repression of DUX4, which is thereby expressed in muscle tissue 45	
[16]. In addition, mutations of SMCHD1 have also been shown to act as disease modifiers in FSHD 46	
patients carrying short or borderline D4Z4 fragments [2,18]. However, the lack of a precise genotype-47	
phenotype correlation in many cases explain the need for a more comprehensive genetic analysis of 48	
both D4Z4 alleles and SMCHD1. In our experience, we observed that the majority of patients with a 49	
clinical suspect of FSHD carry a borderline (8-10RU) or normal (>11RU) sized D4Z4 fragment, in 50	
contrast to patients carrying a short fragment of 1-7RU. In this work, we report the sequence analysis 51	
of SMCHD1 in a cohort of clinically defined FSHD patients in order to assess the distribution of 52	
SMCHD1 variants, considering the D4Z4 size (short fragment, borderline fragment and normal 53	
fragment).  54	
 55	
 56	
Results 57	
NGS and traditional methodologies proved to be useful to characterize D4Z4 fragment, 4qA and 58	
SMCHD1 sequence in the patient’s cohort. We selected a cohort of patients representative the three 59	
categories of patients in terms of fragment size: a number of 30 patients (40%) presenting a normal 60	
range (>11RU), 13 subjects (17%) with borderline (8-10RU) and 33 (43%) patients with short 61	
fragment (1-7RU) (Fig. 1). All the patients resulted to be 4qA-positive. Successively, the sequence 62	
analysis of SMCHD1 was performed in all patients. The extensive analysis of SMCHD1 sequence 63	
revealed the presence of 88 variants scattered throughout the introns, exons and 3’UTR regions of 64	
the gene. The evaluation of frequency distribution and bioinformatics analysis indicated that 8 exonic 65	
variants were described as benign or likely benign, whereas 6 exonic variants were classified as 66	
Variants of Uncertain Significance (VUS) which need to be further investigated (Suppl. Table 1). In 67	
addition, 61 intronic variants were detected, which resulted to have no impact on splicing activity 68	
(Suppl. Table 2). The frequency distribution of the above-described variants are consistent with the 69	
frequency distribution observed in the general population and are not correlated with any of the 70	
fragment size category.  71	
Moreover, the analysis of SMCHD1 sequence pointed out the attention on 7 pathogenic and likely 72	
pathogenic variants in 7 FSHD patients carrying a borderline or normal sized D4Z4 fragment, namely 73	
c.182_183dupGT, c.2129dupC, c.3469 G>T, c.5150_5151delAA and c.1131+2_1131+5delTAAG, 74	
c.3010A>T, c.853G>C (Table 1). 75	
SMCHD1:c.182_183dupGT 76	
The insertion variant c.182_183dupGT (p.Q62Vfs*48) is localized in the exon 1 of SMCHD1 and 77	
has been found in one individual at the heterozygous state. This variant was not present in none of 78	
the annotation databases and has been predicted as disease-causing by Mutation Taster. In fact, the 79	
c.182_183dupGT may create a Premature Termination Codon (PTC), causing the termination of the 80	
amino acid sequence at the 109th amino acid (instead of the canonical 2006th codon), leading thereby 81	
to the activation of Nonsense-mediated mRNA Decay (NMD). The analysis of this variant by 82	
SMART prediction tool revealed that the truncated protein may result in the loss of its essential 83	
functional domains, namely the GHKL-ATPase and the SMC hinge domains. This alteration was also 84	
visible by the comparison of the wild-type (Fig. 2A) and variant 3D model simulated by Phyre2. 85	
Figure 2B illustrates the strong alteration of the protein secondary structures and of the subsequent 86	
conformation of the variant protein compared to the wild-type structure. The analysis on HSF 87	
indicated that the variant may impact the splicing as well, cause the disruption of a donor splice site, 88	
the creation of an Exonic Silencer Site (ESS) or the activation of a cryptic exonic donor site. 89	
According to ACMG, the c.182_183dupGT has been classified as a likely-pathogenic variant 90	
(Table2). As a matter of fact, the variant is a null variant potentially causing Loss Of Function (LOF) 91	
of SMCHD1 (PVS1) and it is absent in ExAc, GnomAD and 1000Genome Browser (PM2). 92	
Concerning D4Z4 region, the patient showed a 10RU contracted fragment. From a clinical point of 93	
view, the patient reported weakness of the scapular girdle muscles with difficulties to rise both the 94	
arms, in combination with an increased level of CPK enzyme (3 times higher than expected). 95	
Therefore, the D4Z4 and SMCHD1 findings (borderline fragment + LOF variant in SMCHD1) 96	
together with the observed clinical features may confirm the clinical suspect of FSHD.  97	
SMCHD1:c.2129dupC 98	
The insertion variant c.2129dupC (p.A711Cfs*11) has been found in the exon 16 of SMCHD1 in a 99	
single individual at the heterozygous state. This variant has not been annotated in any of the online 100	
databases. MutationTaster prediction described the c.2129dupC as a disease-causing variant, since it 101	
may create a frameshift and, consequently, a PTC at the 721th aminoacid and NMD. The analysis of 102	
the variant effect by SMART tool suggested that the truncated protein may lose the C-terminal SMC 103	
hinge domain. Consistently with this data, Phyre2 showed that the 3D model predicted for the variant 104	
protein appeared to have a more compressed conformation (Fig. 2C) with respect to the wild-type 105	
structure (Fig. 2A). The HSF analysis did not reveal a potential alteration of splicing. According to 106	
ACMG, the c.2129dupC can be classified as a pathogenic variant (Table2), since it is a null variant 107	
leading to a LOF of SMCHD1 (PVS1); it is absent in ExAc, GnomAD and 1000Genome Browser 108	
(PM2) and there is computational evidence supporting a deleterious effect on the gene product 109	
without benign-supporting predictions (PP3). D4Z4 sizing revealed a borderline fragment (9RU) in 110	
this patient, while the clinical assessment reported a mild weakness of pelvic and proximal leg 111	
muscles, although the patient was still able to stand up from a chair without support. These data and 112	
the presence of a LOF variant in SMCHD1 support therefore the FSHD-associated clinical 113	
symptomatology. 114	
SMCHD1:c.3469 G>T 115	
The variant c.3469 G>T (p.G1157*) is situated within the exon 27 of SMCHD1 and has been 116	
identified in a single patient at the heterozygous state. This variant has not been reported on the online 117	
annotation databases and has been predicted to have a damaging effect by Mutation Taster. In fact, 118	
the c.3469 G>T creates a frameshift, generating a PTC at the 1157th aminoacid and probably 119	
triggering the NMD process. In addition, the analysis performed by SMART and Phyre2 reported 120	
that the truncated protein may result in the loss of the SMC hinge domain and, consequently, in the 121	
disruption of secondary structure and a partial relaxation of the tridimensional conformation of 122	
SMCHD1 (Fig. 2D). This variant has also been investigated by HSF, showing that it can affect 123	
splicing through the alteration of an Exonic Splicing Enhancer (ESE) site. Following ACMG criteria, 124	
the c.3469 G>T can be described as a pathogenic variant (Table2), since it is a null variant (PVS1), 125	
it is absent on ExAc, GnomAD and 1000Genome Browser (PM2) and has been predicted to be 126	
damaging for the gene or the gene product (PP3). The analysis of D4Z4 reported a borderline fragment 127	
(8RU) in this patient, who experienced a weakness of axial, facial, scapular, lower limbs muscles, 128	
although he maintained the ability to walk on tips. These data and the detection a truncating variant 129	
in SMCHD1 may confirm the supposed FSHD pathology.  130	
SMCHD1:c.5150_5151delAA 131	
The c.5150_5151delAA (p.K1717Rfs*16) has been detected in the exon 41, in a single case at the 132	
heterozygous state. This variant was predicted to have a pathogenic effect, leading to NMD and 133	
causing loss of the C-terminal SMC hinge domain. Moreover, the 3D model obtained by Phyre2 134	
highlighted a maintenance of the central coiled-coil domain conformation in the truncated protein 135	
(Fig. 2E). This variant has been described as a pathogenic variant (Table2) in our previous work, in 136	
which we described an accurate genotype-phenotype correlation within the proband and his family 137	
[19]. However, we decided to include the sample even in the present study because we performed the 138	
3D simulation of the variant protein and we evaluated the 3’UTR region of SMCHD1. 139	
SMCHD1:c.1131+2_1131+5delTAAG 140	
The intronic c.1131+2_1131+5delTAAG variant has been found downstream the exon 9 in one 141	
patient at the heterozygous state. This variant is novel and has been predicted to affect splicing and 142	
lead to NMD. In addition, the c.1131+2_1131+5delTAAG was not found in the annotation databases 143	
and has been reported as a disease-causing variant on MutationTaster. However, the prediction of the 144	
effect on the protein domains could not be performed because it is not possible to predict how the 145	
sequence and the reading frame may be altered following this variant, although it is likely to affect 146	
splicing. According to ACMG guidelines, the variant has been classified as likely-pathogenic 147	
(Table2), considering that it is a null variant (PVS1) and it is not been reported in ExAc, GnomAD 148	
and 1000Genome Browser (PM2). Interestingly, D4Z4 sizing in the patient revealed a fragment 149	
>11RU, which is normally considered as non-pathogenic for FSHD. However, the patient 150	
experienced a severe weakness of pelvic muscles, needing thereby a double support to stand up from 151	
a chair but retaining the ability to walk independently. In this case, the FSHD clinical phenotype may 152	
be explained by the presence of a likely pathogenic variant in SMCHD1. 153	
SMCHD1:c.3010A>T 154	
The c.3010A>T (p.K1004*) has been localized in the exon 24 of SMCHD1 in a single patient at the 155	
heterozygous state. This variant has not been reported on the online annotation databases and has 156	
been predicted to have a damaging effect by Mutation Taster. In fact, the variant has been predicted 157	
to generate a PTC at the 1004th aminoacid, probably triggering the NMD process. The interrogation 158	
of HSF indicated that the variant may affect the splicing as well, causing the creation of an ESS or 159	
the alteration of ESE site. In addition, the analysis performed by SMART and Phyre2 reported that 160	
the truncated protein may result in the loss of the SMC hinge domain and, consequently, in the 161	
disruption of the secondary structure and the tridimensional conformation of SMCHD1 (Fig.2F). The 162	
ACMG classification of c.3010A>T described it as a pathogenic variant (Table2), since it is a null 163	
variant (PVS1), it is absent on ExAc, GnomAD and 1000Genome Browser (PM2) and has been 164	
predicted to be damaging for the gene or the gene product (PP3). The patients carrying this variant 165	
reported a fragment >11RU and experienced a mild weakness of pelvic and proximal leg muscles, 166	
although he was still able to stand up from a chair without support. Considering the genotype and 167	
clinical picture of the patient, the FSHD symptomology could be explained by the presence of a LOF 168	
variant in SMCHD1, although he reported a normal size fragment.  169	
SMCHD1:c.853G>C 170	
The variant c.853G>C (p.G285R) has been detected in the exon 7, in a single patient at the 171	
heterozygous state. It is a missense variant, which has been described as disease-causing by Mutation 172	
Taster. In fact, the variant produces an aminoacid change in the GHKL-ATPase protein domain of 173	
SMCHD1. The HSF did not reveal a potential alteration of splicing. However, the predictive analysis 174	
performed on VarSite reported that the aminoacid substitution may be highly negative in terms of 175	
conserved aminoacid properties because of the change from a neutral (G) to a charged residue (R). 176	
Supporting this finding, interrogation of Missense3D tool revealed a damaging effect on the protein 177	
structure resulting from the steric hindrance, the introduction of a buried charge and the substitution 178	
of a buried Glycine residue, which, in turn, impair the bending of the polypeptide chain (Fig.3A-B). 179	
According to ACMG guidelines, the c.853G>C could be likely-pathogenic (Table2), considering that 180	
it is located in a mutational hotspot within a functional domain of the protein (PM1); it is absent on 181	
ExAc, GnomAD and 1000Genome Browser (PM2); it has been found in other affected family 182	
members (PP1) and has been predicted to be damaging for the gene or the gene product (PP3). The 183	
analysis of D4Z4 sizing in the patient revealed a borderline fragment (9RU). Moreover, the patient 184	
had difficulties in the shoulders abduction and reported muscular hypotrophy proximal to legs. Given 185	
these features, the genetic profile of the patient is consistent with FSHD clinical phenotype. 186	
Analysis of the 3’UTR region 187	
The analysis of the 3’ UTR region of SMCHD1 revealed different variants in our patient’s cohort. 188	
However, our attention was focused on c.*1376A>C (rs7238459); c.*1579G>A (rs559994); 189	
c.*1397A>G (rs150573037); c.*1631C>T (rs193227855); c.*1889G>C (rs149259359), considering 190	
that the variant alleles may disrupt an existing binding site or create a novel binding site for different 191	
miRNAs (Table 3). The rs7238459 reported a MAF= 0.263 in our patient’s cohort; which overlaps 192	
the frequency observed in the general population (MAF= 0.257). According to PolymiRTS, the 193	
variant allele (C) of rs7238459 is able to disrupt a binding site for MIR7850 as well as to create a site 194	
for MIR6740.  195	
The rs559994 had a MAF= 0.263 in our cases, resulting to be lower compared to the general 196	
population (MAF= 0.438). PolymiRTS interrogation revealed that the variant allele (A) may create a 197	
new binding site for MIR548AT.  198	
The rs150573037 has only been detected in two patients (MAF= 0.013). Interestingly, frequency data 199	
for this Single Nucleotide Variation (SNV) are only available for the African population (MAF= 200	
0.008) whereas it has not been observed in the European population up to date. Prediction analysis 201	
indicated that the variant allele (G) of rs150573037 may generate new binding sites for MIR515, 202	
MIR519, MIR519E and MIR5695. 203	
The rs193227855 has been found in two patients (MAF= 0.013) in contrast to the lower frequency 204	
(MAF= 0.006) observed only in the control population of American Ancestry. Based on the 205	
PolymiRTS prediction analysis, this variant may disrupt the binding site for MIR548E and create new 206	
binding sites for MIR495 and MIR548-family members. 207	
Finally, the rs149259359 has been reported in a single patient of the cohort and has been observed 208	
with a low frequency in the general population (MAF= 0.014). Interestingly, this is the patient 209	
carrying the SMCHD1_c.5150_5151delAA and already reported in our previous work [19]. The 210	
segregation analysis on his family members reported the heterozygous presence of the rs149259359 211	
in both the affected mother and maternal uncle. The analysis performed by PolymiRTS revealed that 212	
the variant allele (C) of rs149259359 may disrupt binding sites for MIR3942, MIR4503, MIR4703, 213	
MIR6792 and MIR95, whereas it may create novel binding sites for MIR4477B, MIR651 and 214	
MIR7856.  215	
 216	
Discussion 217	
FSHD is one of the most difficult disease to deal with, because of the complex genetic and epigenetic 218	
background underlying its etiopathogenesis. In fact, the variable penetrance and expressivity 219	
(observed either in related or unrelated patients) does not allow an accurate diagnosis, which is further 220	
complicated by the lack of a precise genotype-phenotype correlation. Although the shortest fragments 221	
have been found in severe patients, most of the mild and moderate cases showed borderline (8-10RU) 222	
or normal-sized (>11RU) fragments (Fig.4). In these cases, the D4Z4 analysis was not enough to 223	
explain the clinical symptomatology. We therefore decided to extend our study to the analysis of 224	
SMCHD1 sequence, which can be helpful for genotype-phenotype correlation in FSHD patients. On 225	
this subject, our previous work described the case of a patient presenting severe FSHD symptoms, in 226	
which preliminary genetic analysis did not clarify the phenotype [19]. In fact, a contracted D4Z4 227	
fragment was detected both in the affected proband and the healthy father, without explaining thereby 228	
the severe symptomatology of the proband and highlighting a reduced penetrance of disease within 229	
the family. The subsequent analysis of SMCHD1 revealed the presence of a novel pathogenic variant 230	
in the proband, which was also detected in the mother and the maternal uncle who were both affected 231	
by mild FSHD symptoms without carrying a short D4Z4 fragment. The severe phenotype of the 232	
proband may therefore be explained by the digenic inheritance of a contracted fragment and a 233	
SMCHD1 variant [19]. In the present study, the analysis of SMCHD1 sequence reported 88 variants 234	
which were localized throughout the introns, exons and 3’UTR regions of the genes. Of them, 69 235	
were classified as polymorphisms with a frequency distribution overlapping those observed in the 236	
general population. These variants are probably not related with FSHD neither with the D4Z4 237	
fragment size, suggesting that they are not involved in disease etiopathogenesis. Moreover, 5 non-238	
described VUS were also detected, but they need to be re-evaluated as more information and/or 239	
literature data will be collected concerning their potential clinical relevance in FSHD. In addition, 240	
none of them are correlated with a specific class of D4Z4 fragment size.  241	
Interestingly, 7 pathogenic and likely pathogenic variants were identified by SMCHD1 sequencing, 242	
namely c.182_183dupGT, c.2129dupC, c.3469 G>T, c.1131+2_1131+5delTAAG, 243	
c.5150_5151delAA, c.3010A>T and c.853G>C. All of them were found to strongly impact the 244	
protein structure. In fact, these variants were predicted to disrupt the structure and conformation of 245	
SMCHD1 and, in most cases, alter splicing or create PTC and truncated protein products. The 246	
resulting protein have been predicted to cause the loss of GHKL-ATPase and SMC hinge domains, 247	
which are essential for SMCHD1 to maintain a repressive chromatin structure in muscle cells. These 248	
results are in line with the FSHD etiopathogenetic mechanism, which supports a toxic expression of 249	
DUX4 as a consequence of LOF mutations in SMCHD1. However, functional assays are necessary to 250	
validate the real effect of the identified variants on the protein structure and function. Interestingly, 251	
gain-of function mutations localized in GHKL-ATPase domain of SMCHD1 have been shown to 252	
cause severe malformations of the human nose, olfactory tract and eyes (namely, Bosma arhinia 253	
microphthalmia syndrome; BAMS), whereas LOF or dominant-negative pathogenic SMCHD1 254	
mutations have been found throughout the sequence of the gene [20]. Why mutations of SMCHD1 255	
lead to the development of FSHD rather than BAMS is still a matter of investigation. However, these 256	
data emphasize the importance of considering the genetic background of patients to clarify the clinical 257	
variability of such disorders. The present study showed that the analysis of D4Z4 fragment and 258	
SMCHD1 sequence were crucial to confirm the suspected clinical phenotype and accomplish a 259	
reliable genotype-phenotype correlation. Our data are consistent with Sacconi et al., 2019 who 260	
suggested that a borderline D4Z4 fragment might be considered as a risk factor or a phenotype 261	
modifier of FSHD in patients carrying SMCHD1 causative mutations [21]. On the other hand, patients 262	
with borderline D4Z4 fragment who were negative to SMCHD1 analysis, could not receive a clear 263	
molecular diagnosis, although they appeared phenotypically affected. This data highlights the fact 264	
that probably one or more unknown genes contribute to determine the permissive background for 265	
FSHD. On this subject, a recent study identified a potentially damaging mutation in the DNA 266	
Methyltransferase 3 Beta (DNMT3B, 20q11.21, #602900) gene, which is a D4Z4-chromatin modifier 267	
and, therefore, it represent a good candidate gene for FSHD [2,18,23]. In this context, we developed 268	
an NGS panel, including a set of candidate genes involved in the epigenetic regulation of the D4Z4 269	
region and genes targeted by DUX4 (data in progress). Moreover, the analysis of SMCHD1 sequence 270	
revealed the presence of variants in the 3’ UTR region of the gene, which may affect the binding of 271	
specific miRNAs or their interaction with target mRNAs. In this perspective, the rs149259359 (G/C) 272	
appeared to be the most interesting among the identified 3’ UTR variants. In fact, the variant allele 273	
(C) of the SNP was predicted to disrupt the binding sites of different miRNAs, including MIR95, 274	
which is known to be overexpressed during myogenic differentiation [24]. A disruption of its binding 275	
site, may thereby affect the expression of MIR95 and its modulatory effect in myogenic cells, 276	
suggesting a potential role as a disease modifier in FSHD. Given the fact that the variant has been 277	
identified in the patient carrying the c.5150_5151delAA, we performed segregation analysis on his 278	
family members. Interestingly, the rs149259359 was detected in both the affected mother and 279	
maternal-uncle, supporting its potential implication in FSHD etiopathogenesis or severity. These 280	
findings support the role of epigenetics as hallmark and/or phenotype modifier of disease [22].  281	
Altogether, the present study highlight how NGS platforms can be helpful to disclose SMCHD1 as 282	
well as other candidate genes effect in FSHD pathogenesis. However, NGS still needs to be always 283	
combined with labor-intensive, outdated genetic methodologies (such as southern blotting) to better 284	
characterize the complex etiopathogenetic background of FSHD. On this subject, the recent 285	
development of alternative molecular approaches, including molecular combing and optical mapping 286	
platforms, proved to be the most feasible alternatives for FSHD molecular diagnosis and investigation 287	
[2]. Moreover, a deeper characterization of the leading mechanisms underlying the disease can be 288	
critical for undertaking the most suitable molecular assays and enable an accurate genotype-289	
phenotype correlation [25-26]. In this perspective, integrating molecular findings and clinical data is 290	
essential to develop precision medicine protocols for FSHD patients.  291	
 292	
Methods 293	
Description of patients’ cohort 294	
The study involved 76 Italian individuals with a clinical suspect of FSHD enrolled at the Gemelli 295	
University Hospital Foundation of Rome and the University of Campania “Luigi Vanvitelli”. 296	
Recruited patients had an average age of 50 years and a 47:53 male/female ratio. The clinical 297	
evaluation of patients was performed by specialized physicians following the dedicated guidelines 298	
[26-27]. All participants provided signed informed consent for research and publication at the time 299	
of recruitment. The study was approved by the ethics committee of Santa Lucia Foundation and 300	
complied with Declaration of Helsinki. 301	
 302	
DNA extraction and D4Z4 analysis  303	
The DNA was initially extracted from lymphocytes according to standard procedures. Successively, 304	
the extracted DNA was digested on agarose plugs by EcoRI, EcoRI/BlnI and XapI restriction 305	
enzymes and subsequently separated by Pulsed-Field Gel Electrophoresis (PFGE) as previously 306	
described [19]. The D4Z4 RU were evaluated by southern blotting and hybridization with p13E-11 307	
probe according to standard procedures. Linear Gel Electrophoresis (LGE) was utilized to confirm 308	
the results. In addition, 4qA and 4qB alleles were subjected to digestion with HindIII and EcoRI, 309	
PFGE and southern blot hybridization with radio-labeled 4qB and 4qA probes, according to standard 310	
procedures [19]. 311	
SMCHD1 sequence analysis 312	
SMCHD1 gene was extensively investigated by Next Generation Sequencing (NGS) and direct 313	
sequencing, searching for putative variants located within the intronic, exonic and 3’UTR regions. 314	
To this purpose, the DNA was re-extracted from 400 µl of peripheral blood using MagPurix Blood 315	
DNA Extraction Kit and MagPurix Automatic Extraction System (Resnova) according to the 316	
manufacturer’s instructions. SMCHD1 gene was sequenced using Ion Torrent S5 and Ion Ampliseq 317	
Customized Panel, designed by Ion Ampliseq Designer (Thermo Fisher Scientific). The panel is 318	
expected to screen approximately 99.72% of target sequences, considering a minimum coverage of 319	
20X. The construction of the library was performed by Ion AmpliSeqTM Library Kits Plus and 320	
utilizing approximately 10 ng/µl of starting DNA for multiplex PCR reactions. Two purification steps 321	
(using AMPure XP, Beckman Coulter) were performed to remove unwanted contaminants, followed 322	
by a final PCR according to manufacturer’s instruction. The quality of library was evaluated by Qubit 323	
R 2.0 Fluorometer (Thermo Fisher Scientific). The enrichment procedures were performed by Ion 324	
Chef System (Thermo Fisher Scientific). Ion 510TM & Ion 520TM & Ion 530TM Kit-Chef (Thermo 325	
Fisher Scientific) were utilized for template amplification, enrichment and sequencing. Samples were 326	
run on Ion 520TM Chip (850 flows required) and Ion Torrent S5 (Thermo Fisher Scientific). The 327	
results were analyzed using Ion Reporter 5.6 (Thermo Fisher Scientific), Integrated Genome Viewer 328	
(IGV), taking the hg19 as reference genome building and NM_015295.2 as reference sequence for 329	
SMCHD1. The putative variants and SMCHD1 sequence regions uncovered by NGS were analyzed 330	
by direct sequencing. To this purpose, 100 ng/µl of genomic DNA was amplified using the AmpliTaq 331	
Gold DNA Polymerase (Applied Biosystems) and PCR reagents in a total volume of 25 µL, following 332	
manufacturer’s instructions. The amplified samples were sequenced using Big Dye Terminator v3.1 333	
Cycle Sequencing Kit (ThermoFisher Scientific) and run on ABI3130xl (Applied Biosystems). 334	
Electropherograms were finally analyzed with Sequencing Analysis Software v.6 (Applied 335	
Biosystems).  336	
 337	
 338	
 339	
Interpretation of variants 340	
The identified variants were firstly investigated by looking at frequencies and data reported on 341	
publicly available database (1000Genome browser, ExAC, Clinvar, HGMD, GnomAD). UniProt 342	
annotation database [29] was used to obtain the aminoacid sequence and the protein domains of wild-343	
type SMCHD1. The functional effect of the detected variants was evaluated by bioinformatic 344	
predictive tools, including Mutation Taster, Varsome, SMART, Human Splicing Finder (HSF), 345	
Phyre2, VarSite, Missense3D. In particular, MutationTaster evaluates the potential pathogenic effect 346	
of DNA sequence alterations by predicting the functional consequences of amino acid substitutions, 347	
intronic and synonymous alterations, short insertions and/or deletions (indels) and variants spanning 348	
intron-exon borders affecting splicing activity [30]. Varsome is a powerful annotation tool and search 349	
engine for human genomic variants, allowing the classification of variants according to ACMG 350	
criteria [31]. SMART, VarSite, Missense3D and Phyre2 enable the prediction of the effect of the 351	
variants on the protein structure (Kelley et al., 2015; Letunic et al., 2015; Letunic et al., 2018) [32-352	
36]. In particular, SMART performs the analysis of the architecture of protein domains whereas 353	
Phyre2, VarSite and Missense3D are able to analyze the effect of aminoacid changes on protein 354	
structure, providing a 3D model of the predicted results. HSF predicts the effects of variants on the 355	
splicing mechanisms [37]. PolymiRTs Database 3.0 was used to analyze the variants detected within 356	
the 3’ untraslated region (3’UTR) of SMCHD1. It allows the evaluation of the functional impact of 357	
genetic variants located in microRNA (miRNAs) seed regions and miRNAs target sites, predicting 358	
the effect on the miRNA-mRNA binding (Bhattacharya et al., 2014) [38]. 359	
Taking into account frequency and predictive results, the variants of SMCHD1 have been classified 360	
according to the American College of Medical Genetics (ACMG) Standards and Guidelines, which 361	
help providing clinical interpretation of variants, by discriminating among benign, likely benign, 362	
uncertain significance, likely pathogenic and pathogenic variants (Richards 2015) [39]. 363	
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Tables 486	
Table 1: Genetic characterization of the SMCHD1 mutations identified in 7 FSHD patients. 487	
Patient ID D4Z4 size 4qA SMCHD1_variant position SMCHD1_HGVS nomenclature 
I 10RU + 18:2656257_2656258 c.182_183dupGT 
II 9RU + 18:2707627_2707628 c.2129dupC 
III 8RU + 18:2739473 c.3469 G>T 
IV >11RU + 18:2697122_2697125 c.1131+2_1131+5delTAAG 
V 8RU + 18:2772345_2772346 c.5150_5151delAA 
VI >11RU + 18:2729369 c.3010A>T 
VII 9RU + 18:2688725 c.853G>C 
 488	
 489	
 490	
 491	
 492	
 493	
 494	
 495	
 496	
 497	
 498	
 499	
 500	
 501	
 502	
 503	
 504	
 505	
Table 2: Prediction analysis and ACMG classification of the 7 SMCHD1mutations. 506	
ESS: Exonic Silencer Site; ESE: Exonic Splicing Enhancer; WT: wild-type. 507	
SMCHD1 mutations MutationTaster SMART Human Splicing Finder ACMG 
c.182_183dupGT Disease causing 
Loss of GHKL-
ATPase domain 
and SMC hinge 
domain 
Disruption of a donor splice 
site; activation of an exonic 
cryptic donor site or 
creation of an ESS 
Likely 
pathogenic 
c.2129dupC Disease causing Loss of SMC hinge domain 
No significant splicing 
motif alteration detected Pathogenic 
c.3469 G>T Disease causing Loss of SMC hinge domain Alteration of an ESE Pathogenic 
c.5150_5151delAA Disease causing Loss of SMC hinge domain 
Creation of an ESS or 
alteration of an ESE Pathogenic 
c.1131+2_1131+5delTAAG Disease causing NA Alteration of the WT donor site 
Likely 
Pathogenic 
c.853G>C Disease causing 
No significant 
alteration of 
domain 
organization 
No significant splicing 
motif alteration detected 
Likely 
Pathogenic 
c.3010A>T Disease causing Loss of SMC hinge domain 
Creation of an ESS or 
alteration of an ESE Pathogenic 
 508	
Table 3: Bioinformatic prediction of 3’UTR variants altering the match to the miRNA seed region. 509	
MAF: Minor Allele Frequency. *Calculated on 76 patients, # Referred to 1000Genomes allele frequencies  510	
Genomic 
position SNP 
MAF 
FSHD* 
MAF 
EUR# 
Effect of the variant 
allele Targeted miRNA 
18:2803926 rs7238459 (A/C) C: 0.263 C: 0.257 
Disruption of a conserved 
miRNA site MIR-7850 
Creation of a new miRNA 
site 
MIR-6740 
18:2804129 rs559994 (G/A) A: 0.263 A: 0.438 
Creation of a new miRNA 
site MIR-548AT 
18:2804439 rs149259359 
(G/C) 
C: 0.006 C: 0.014 
Disruption of a conserved 
miRNA site 
MIR-3942 
MIR-4503 
MIR-4703 
MIR-6792 
MIR-95 
Creation of a new miRNA 
site 
MIR-4477B 
MIR-651 
MIR-7856 
18:2803947 rs150573037 
(A/G) 
G: 0.013 G: 0.000 Creation of a new miRNA 
site 
MIR-515 
MIR-519D 
MIR-519E 
MIR-5695 
18:2804181 rs193227855 (C/T) T: 0.013 T:0.000 
Disruption of a conserved 
miRNA site 
MIR-548E 
Creation of a new miRNA 
site 
MIR-495 
MIR-548AC 
MIR-548AE 
MIR-548AH 
MIR-548AJ 
MIR-548AM 
MIR-548AQ 
MIR-548D 
MIR-548H 
MIR-548J 
MIR-548X 
MIR-548Z 
MIR-5688 
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Figure Legends 519	
Fig. 1: distribution of the D4Z4 fragment size which have been subdivided in order to distinguish 520	
short (1-7RU), borderline (8-10RU) and normal sized (>11RU) fragments. RU: Repeated Units.  521	
Fig. 2: A. Predicted conformation of the three wild-type domains of SMCHD1, based on the domain 522	
organization released by Uniprot (Entry: A6NHR9). In particular, the N-terminal region (1-702 AA) 523	
harboring the GHKL-ATPase domain (111-702 AA) is based on the template c5ix1A (PDB header: 524	
transcription; PDB Molecule: morc family cw-type zinc finger protein 3; PDBTitle: crystal structure 525	
of mouse morc3 atpase-cw cassette in complex with2 amppnp and h3k4me3 peptide). The central 526	
coiled-coil domain (703-1719 AA) is based on the template c4e9lA (PDB header: cell adhesion; PDB 527	
Molecule: attaching and effacing protein, pathogenesis factor; PDBTitle: fdec, a novel broadly 528	
conserved escherichia coli adhesin eliciting 2 protection against urinary tract infections). The C-529	
terminal region (1720-2005 AA) harboring the SMC hinge domain (1720-1847AA) is based on 530	
c2wd5A (PDB header: cell cycle Chain: A: PDB Molecule: structural maintenance of chromosomes 531	
protein 1a; PDBTitle: smc hinge heterodimer (mouse). B-F: 3D model predicted by Phyre 2 tool. The 532	
structure resulting from the presence of the c.182_183dupGT (B) is based on the template d1e9ya1 533	
(Fold: beta-clip Superfamily: Urease, beta-subunit). The structures resulting from the presence of the 534	
c.2129dupC and c.3469G>T (C and D, respectively) are based on the template c5ix1A (PDB header: 535	
transcription. PDB Molecule: morc family cw-type zinc finger protein 3). The structure resulting 536	
from the c.5150_5151delAA (E) is based on the template c4e9IA (PDB header: cell adhesion; PDB 537	
Molecule: attaching and effacing protein, pathogenesis factor). The structure referred to the 538	
c.3010A>T (F) is based on the template c5ix1A (PDB header: transcription. PDB Molecule: morc 539	
family cw-type zinc finger protein). The 3D model simulation of the 540	
SMCHD1_c.1131+2_1131+5delTAAG is not available because the aminoacid sequence alteration 541	
following this variant cannot be predicted.  542	
Fig. 3: predicted structure of the N-terminal region structure of SMCHD1 showing the aminoacid 543	
change resulting from the c.853G>C. The predicted models are based on the on the template c5ix1A 544	
(PDB header: transcription; PDB Molecule: morc family cw-type zinc finger protein 3; PDBTitle: 545	
crystal structure of mouse morc3 atpase-cw cassette in complex with2 amppnp and h3k4me3 peptide). 546	
A. SMCHD1 structure showing the wild-type residue (G). B. SMCHD1 structure showing the variant 547	
residue (R). 548	
Fig. 4: histogram reporting the non-linear correlation between the D4Z4 fragment size and the 549	
severity of disease in the patient’s cohort analyzed in the present study. RU: Repeated Units.  550	
